TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Rocuronium amount
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversion to Sinus Rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Pterygium Hyperemia Responders at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Severity Grade of Pterygium Hyperemia at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numeric Pain Rating System (NPRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative use of morphine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: SARS-Cov-2 positivity rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: IKDC subjective score variation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of HIV mRNA Decline in Peripheral Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of HIV mRNA Expression Decline in Lymphatic Tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD4+ T Cell Number Increase in Peripheral Blood Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD4+ T Cell Increase Quantified in Lymphatic Tissues Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Filter survival time
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients with early filter clotting
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients according to final filter clotting grading
Endpoint domain: Adverse events/effects
Primary endpoint: severity of lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Adherence to Study
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient Exit Study Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence Rate of FVIII-inhibitors ≥0.6 BU
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Annualised Bleeding Rate in the Prophylaxis Arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Return to work from sick leave
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of actively participating practices
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Relative numbers of screened, documented and followed-up patients
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of Kudiezi (Yueanxin) ADRs
Endpoint domain: Adverse events/effects
Primary endpoint: Bitter taste
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With TEAEs, TESAEs and Drug-related TEAEs and TESAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of prescribed drugs acquired
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Accordance of prescribed treatment with proposed guidelines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical outcome of each participant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response shift in patients with schizophrenia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: pharmacokinetic data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morning level of high sensitivity troponin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dome impaction reduction measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SARS-CoV-2 serology results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Amount of bone gained
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Ulcers closed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in average early morning blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Body Mass Index (BMI) Standard Deviation Score (SDS) from Baseline to 16 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Body Mass Index (BMI) Standard Deviation Score (SDS) from Baseline to 52 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensitivity of Xpert® Bladder Cancer Monitor Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity of urinary cytology test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Objective Response Rate (ORR) per RECIST 1.1 by Investigator Assessment at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in sputum mucin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Summed Pain Relief plus Pain Intensity Difference (SPRID) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: age-adjusted BMI standard deviation score (BMI-SDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: EIFEL score evolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimal residual disease (MRD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in isokinetic muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in maximal oxygen consumption (VO2-max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean fold rise of VZV antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean titers of VZV antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of Intracerebral lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent Change From Baseline in NT-proBNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of hyperfibinolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Month 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects With Symptomatic, Laboratory-confirmed Influenza Virus Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Baseline systolic, diastolic, and mean blood pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Baseline sympathetic nerve activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mTICI Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Subject Outcome
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Movement Imagery Questionnaire-3 (MIQ-3)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rating of Physician's Compassion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence rate of treatment emergent ocular and non-ocular adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical pulmonary infection score (CPIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence Rates of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma pharmacokinetic profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibiotic usage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Laboratory testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time from first visit to treatment initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-dose PERMP-T Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Subjects Achieving ≥ 2 Point Improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Fugl-Meyer Assessment (FMA) - Upper Extremity Subtest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Wolf Motor Function Test (WMFT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline on Confidence in Arm and Hand Movement (CAHM) Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Dystrophin Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of Unacceptable Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Time to regression of jaundice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity of immuno-PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean value of the maximum observed concentration (Cmax) of E2082
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean value of the area under the concentration-time curve (AUC[0-24h]) of E2082
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean value of terminal elimination phase half-life (t½) of E2082
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment-related Grade 4 Hemorrhage, Grade 4 Febrile Neutropenia, or Grade 5 Adverse Event (AE), or Discontinuation of Treatment Due to Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Generalized Anxiety Disorder scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: disease response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Restless Leg Syndrome Index
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Worst low back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Relief of hydronephrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Participants With Dose Limiting Toxic Events
Endpoint domain: Adverse events/effects
Primary endpoint: Detection rate per Patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of In-patient Physical Therapy visits required for discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants Achieving PASI 75
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time to First Recurrence of ECG documented AF, AFl or AT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of the Sernova Cell Pouch™
Endpoint domain: Adverse events/effects
Primary endpoint: Response to isoproterenol during bronchial potential difference test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Patients With a Score of Zero for Anterior Chamber Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Percentage of Patients With no Ocular Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Hepatotoxicity events
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Curve (AUC) for whole blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) for plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relapse in the first 12 months after achieving first complete remission
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of adverse effects or events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Days Abstinent
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: # of Drinks Per Drinking Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cue-induced Craving
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage Change in Generalized Tonic-clonic Seizure Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Cognitive assessment results
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Heart sound recordings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood collection results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uric acid stone formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in appetite stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain & Inflammatory Signs & Symptoms of Acute Tonsillitis and/or Acute Pharyngitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants that develop Opportunistic infections
Endpoint domain: Adverse events/effects
Primary endpoint: Resection rate of thymus tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Acute Pain Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Life Quality of Patients
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Myasthenia Gravis remission rate
Endpoint domain: Mortality/survival
Primary endpoint: Skin biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Composite autonomic severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Physical activity levels - multisensor monitor
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline in Physical activity levels - Human Activity Profile
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline in sedentary behavior - multisensor monitor
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Average Daily Low Back Pain Index Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laryngomalacia Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Newborn anthropometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fracture resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Plasma concentration of ceritinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of subjects with an average AUC between 30-60 ng x hr/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-year freedom from failure (FFF)
Endpoint domain: Mortality/survival
Primary endpoint: Mean fatigue level
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Maximum Plasma Concentration at steady state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the Plasma concentration curve (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Percent Change in Reflective Total Nasal Symptom Score (rTNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Percent Change in Instantaneous Total Nasal Symptom Score (iTNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Percent Change in Reflective Total Ocular Symptom Scores (rTOSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Percent Change in Instantaneous Total Ocular Symptom Scores (iTOSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of unscheduled visits
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) of avapritinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with adverse and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended Phase 2 dose (RP2D) of avapritinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in overall score of the Hamilton Rating Scale for Depression (HDRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Body Weight Average 6 Months Post-Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Excess Body Weight Loss at 6 Months Post-Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average Ghrelin Hormone Levels at 6 Months Post-Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cumulative Frequency of CV-related Hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in 6MWT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of fat in the stools
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Migraine improvement responder rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mortality Rate Among COVID-19 Patients
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of Patients with COVID-19 who Require ICU-Level Care, MV, and/or ECMO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients with COVID-19 who Develop Shock, Secondary Organ Failure, or Secondary Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Mobility of the metatarso-phalangeal joint of the hallux
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levine DW Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of sleep after caffeine intake
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change of brain blood-oxygen-level-dependent activity after caffeine intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hair follicle density and percent anagen hairs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: palmar sweat duct number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pilocarpine-stimulated sweat rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose delay or reduction
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Discontinuation of chemotherapy due to toxicity
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of Sustained Viral Response at 12 weeks (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of LUTS/BPH symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IG and IPF concentration for early sepsis identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of neonatal traumatism risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in RV/LV ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of cesarean section
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Stages of Fibrosis based on METAVIR Scoring System
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Stages of Fibrosis based on Ishak Scoring System
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Segmental systolic peak strain and strain rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity of the Breath Test in Detecting H.Pylori Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Specificity of the Breath Test in Detecting Absence of H.Pylori Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Overall Agreement in Determining Presence or Absence of H.Pylori Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes